Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Hims & Hers Health (NYSE: HIMS) has been a top healthcare stock to own over the past five years, soaring by around 350% during that stretch. By focusing on offering customers personalized ...

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company ...

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular weight-loss drugs today. Additionally, the FDA last week hindered the ...